# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-22T17:08:24.193566

---

**Idea Fidelity**

The paper largely follows the original manifest. It uses the staggered transposition of Directive 2019/1023 across EU countries, relies on the Eurostat quarterly bankruptcy index sts_rb_q as the primary outcome, and implements Callaway and Sant’Anna (2021) to exploit differential timing in a DiD framework with a COVID-stringency control. However, the paper omits the manifest’s discussion of complementary annual business demography data (bd_hgnace_r) and the compositional check on business registrations, which could have strengthened the argument that aggregate counts capture actual firm survival rather than mere relabeling. The identification strategy is stated, but the robustness to alternative data sources and the checks for reclassification versus rescue remain underdeveloped.

---

**Summary**

This manuscript exploits the staggered transposition of the EU Preventive Restructuring Directive across 26 member states between 2021 and 2023 to estimate its impact on quarterly bankruptcy declarations, using a Callaway–Sant’Anna staggered DiD estimator supplemented by TWFE and robustness checks. The main finding is a precisely estimated null effect: no detectable reduction (or increase) in formal bankruptcy filings following transposition, which the author interprets as evidence consistent with a reclassification story rather than a rescue of extra firms. The result invites skepticism about the Commission’s projections that preventive restructuring alone saves viable enterprises.

---

**Essential Points**

1. **Threats to Identification from Post-COVID Dynamics & Treatment Timing**

   The directive’s implementation overlaps with large secular recovery in bankruptcy filings after COVID-related moratoria lifted. The paper controls for a quarterly stringency index, but it should better demonstrate that the parallel trends assumption holds in the presence of these nation-specific pandemic responses. The event study shows imprecise coefficients and a marginal pre-trend at $t-7$, but it does not convincingly show that treated and untreated countries followed similar counterfactual paths once pandemic-induced heterogeneity is considered. Given the simultaneous policy shocks (national moratoria, differing pandemic severity), the identifying variation may be confounded. The robustness of the Callaway–Sant’Anna estimates to differential pre-trends, especially since the treatment spans such a short window (2021–2023), needs much stronger defense—e.g., by exploiting additional control outcomes or proving that the COVID stringency index fully absorbs varying moratoria effects.

2. **Outcome Measure Cannot Distinguish Restructuring vs Liquidation; Interpretation of Null is Overstated**

   The paper’s conclusion hinges on interpreting a null effect on aggregate bankruptcy declarations as evidence for “reclassification.” Yet the bankruptcy index does not distinguish between restructurings and liquidations, and the paper lacks alternative outcomes that could detect compositional shifts. Moreover, since many countries already had restructuring procedures, the “treatment” may only upgrade existing filings rather than add new ones, weakening the interpretation of a null as a failure to rescue firms. Without data on the composition of filings (liquidation vs restructuring) or business survival rates, the claim that the directive “relabeled proceedings rather than rescuing firms” remains speculative. This issue is central to the research question and must be addressed through either supplemental data or a more cautious framing.

3. **Limited Evidence that Treatment Intensity Varies Enough to Identify an Average Effect**

   The directive’s implementation across countries is heterogeneous: some countries merely codified practices already in place, while others introduced genuinely new procedures. If “treatment intensity” is low in many jurisdictions, the average ATT may be zero even if impactful in high-intensity settings. The paper acknowledges this but provides no empirical way to distinguish “weak” from “strong” treatment. Without a measure of actual enforcement or usage (e.g., number of preventive restructuring filings or legal practitioner counts), there is a real risk that the paper estimates a weighted average of near-zero effects, masking heterogeneity. The identification strategy must therefore be complemented with either a treatment intensity proxy or subgroup analysis that isolates jurisdictions where the directive was truly transformative.

Given these issues, I am concerned that the paper does not yet provide a credible causal link between the directive and bankruptcy dynamics. If the authors cannot convincingly defend the parallel trends assumption, address the compositional ambiguity of the outcome, and incorporate treatment intensity heterogeneity, the paper’s central conclusion lacks sufficient support.

---

**Suggestions**

1. **Strengthen Parallel Trends Evidence**
   - Provide more detailed comparisons of pre-treatment trends between early and late adopters, perhaps by matching on pre-trend trajectories or by explicitly modeling country-specific pandemic effects (e.g., interacted pandemic stringency with country dummies). This could include lead-lag event studies with bootstrapped confidence bands or synthetic control-style checks. Demonstrating that not-yet-treated countries form a credible counterfactual in each cohort is essential.
   - Consider re-estimating the Callaway–Sant’Anna model with cohort-specific trending adjustments or including leads of the treatment variable to control for anticipatory behavior that might bias the ATT (especially since firms and courts may anticipate impending reforms).

2. **Incorporate Additional Outcomes or Proxy Measures**
   - If possible, leverage the bd_hgnace_r data referenced in the manifest to examine survival rates, re-registration patterns, or industry-level demography changes. Even annual data can complement the quarterly bankruptcy index by showing whether firm survival increased post-transposition.
   - Alternatively, construct a proxy for restructuring usage—perhaps from national insolvency service reports or Eurostat data on “restructuring proceedings” (if available)—to assess whether preventive restructuring filings rose while bankruptcies remained flat. This would help distinguish reclassification from actual reductions in liquidations.
   - Use business registration data (e.g., from Eurostat’s business demography indicators) to test whether total firm exits (including informal closures) moved in sync with formal insolvencies. If registrations and closures move together, it would lend credence to the null being meaningful.

3. **Explore Treatment Intensity Heterogeneity**
   - Build an index of “transposition depth” capturing whether a country already had similar procedures (e.g., dummy for pre-existing restructuring law) or based on legal summaries of how transformative each national law was. Then interact this index with the treatment indicator to see if stronger reforms yielded detectable effects.
   - Alternatively, focus on a subset of countries that had weak pre-existing frameworks (e.g., Eastern and Southern Europe) and check whether the directive had any effect there, even if the aggregate remains null.
   - Examine whether legal capacity constraints (court budgets, insolvency practitioner counts) moderate the treatment effect—if the treatment only becomes operative where courts can implement it, restricting attention to those cases would provide more interpretable results.

4. **Revisit Interpretation and Framing**
   - Reframe the policy conclusion to emphasize the limits of the data rather than suggesting the directive “failed” to save firms. Acknowledge explicitly that the chosen outcome cannot detect compositional changes and that the directive could still have affected restructuring quality, recovery values, or informal workouts.
   - Present the null as informative but not conclusive by discussing the power of the test and the smallest effect size that could have been detected. A power calculation (or at least a discussion of the precision of the estimate relative to policy-relevant effect sizes) would help policymakers interpret the meaningfulness of the null.

5. **Address Standardized Effect Size Table and Classification**
   - The appendix’s standardized effect size table classifies moderate-to-large positive effects even when estimates are statistically insignificant. Clarify that this classification refers to point estimates relative to outcome variation, not estimated impacts, and consider removing the “classification” column if it confuses interpretation.
   - If keeping it, align the classification with the main result; otherwise, readers may infer the directive had large positive effects even though the estimate is a null.

6. **Supplement with Qualitative or Implementation Information**
   - Include a brief discussion or table summarizing implementation dates alongside qualitative notes on each country’s pre-existing framework, court capacity, or administrative innovations. This context would help readers understand why some countries may show stronger effects and would also strengthen the argument about institutional inertia.

7. **Re-run the Placebo with Alternative Window**
   - The placebo in Table 4 uses a −4 quarter shift but is estimated only on the pre-period, which truncates the sample. Running an event-study placebo that extends farther back (perhaps −8 to −1) and including all countries could provide a cleaner check for spurious effects, particularly given the wide event-time confidence bands.

By addressing these points, the authors can bolster the credibility of their identification strategy, clarify the interpretation of the null result, and provide more nuanced policy takeaways.
